Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03491553 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT03491553 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 48 participants.
The verdict
NCT03491553, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the safety, tolerability and antiviral activity of selgantolimod (formerly GS-9688) in virally suppressed chronic hepatitis B (CHB) adults on oral antiviral (OAV) agents.
Interventions
- DRUG Placebo
- DRUG Selgantolimod
- DRUG Hepatitis B virus (HBV) OAV Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-04-06 |
| Est. Completion | 2020-08-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03491553
The ClinicalTrials.gov registry entry for NCT03491553 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03491553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03491553 about?
NCT03491553 is a clinical study titled "Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B". The primary objectives of this study are to evaluate the safety, tolerability and antiviral activity of selgantolimod (formerly GS-9688) in virally suppressed chronic hepatitis B (CHB) adults on oral antiviral (OAV) agents.
What is the current status of trial NCT03491553?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2018-04-06. Estimated completion is 2020-08-10.
What interventions are being tested in trial NCT03491553?
The interventions under investigation include: Placebo (DRUG), Selgantolimod (DRUG), Hepatitis B virus (HBV) OAV Therapy (DRUG).
Who is sponsoring clinical trial NCT03491553?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.